Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KLF6
REST API REST API
Homo sapiens
KLF6 is differentially expressed in 390 experiments: 160 organism parts: lung, liver, ... (158 more);, 238 disease states: normal, acute myeloid leukemia, ... (236 more);, 117 cell types 471 cell lines 70 compound treatments and 86 other conditions.
Synonyms CPBP, BCD1, COPEB, Zf9, PAC1, GBF, ST12
Orthologs Q5ZI79_CHICK (Gallus gallus)   KLF6 (Bos taurus)   ENSCING00000001563 (Ciona intestinalis)   Klf6 (Rattus norvegicus)   copeb (Danio rerio)   Klf6 (Mus musculus)   luna (Drosophila melanogaster)   KLF6 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, cytokine-mediated signaling pathway, cytoplasm, double-stranded DNA binding, intracellular, transcription, DNA-dependent, wound healing, metal ion binding, nucleic acid binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, positive regulation of transcription, DNA-dependent, zinc ion binding, B cell differentiation, sequence-specific DNA binding transcription factor activity
UniProt Accession Q99612, O43838, Q7Z3W8, E7ETR4, F5H3M5
Gene-Disease Assocation PROSTATE CANCER, GASTRIC CANCER, GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC
Search EB-eye ENSG00000067082
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529, E-GEOD-19639
MDA-MB-231
3
E-GEOD-5823, E-MTAB-62, E-TABM-420
BT-474
2
E-GEOD-3529, E-GEOD-5823
HCC2157
2
E-MTAB-37, E-MTAB-62
Jurkat
2
E-MEXP-2197, E-GEOD-1880
LNCaP
2
E-GEOD-14990, E-GEOD-14464
465 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (53 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-3920, E-GEOD-3998, E-GEOD-19240
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD4+ T cell
1
2
E-GEOD-16190, E-AFMX-5, E-TABM-145
primary fibroblast
1
E-MEXP-66
111 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (84 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-62, E-MTAB-37, E-MEXP-231, E-GEOD-2514
colon carcinoma
1
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57, E-MTAB-37
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
ulcerative colitis
2
E-GEOD-3365, E-MTAB-62
232 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1045, E-GEOD-5542, E-GEOD-5741, E-TABM-782, ... (44 experiments)

Factor Value U/D Experiments
none
4
12
E-GEOD-20719, E-GEOD-6907, E-TABM-782, E-GEOD-412, E-GEOD-995, ... (16 experiments)
control
3
E-GEOD-3284, E-GEOD-440, E-GEOD-4006
17beta-estradiol
4
2
E-GEOD-2292, E-GEOD-4006
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
Cxcl12
1
E-GEOD-7307
R547
1
E-GEOD-15389
64 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
74.51
1
1
E-TABM-325


Age years
studied in E-TABM-783

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-3624, E-TABM-321, E-TABM-868, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-21612, E-GEOD-20540, E-GEOD-10315, E-TABM-440, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (42 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (9 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-595, E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-4600, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16193, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.36 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM